Dr. Rana Wajahat, MD

Dr. Wajahat practices at OSF Little Company of Mary Medical Center in Evergreen Park, Illinois, part of OSF HealthCare System.

Dr. Wajahat's NPI, 1619354966, was assigned on May 6, 2015. Dr. Wajahat holds Ohio license 35135867.

Dr. Wajahat's primary practice is OSF Little Company of Mary Medical Center, at 2800 W 95th St, Evergreen Park, IL 60805 in Cook County. The practice phone is (708) 422-6200.

Dr. Wajahat's primary practice is OSF Little Company of Mary Medical Center in Evergreen Park, Illinois, part of OSF HealthCare System. Dr. Wajahat is also affiliated with University of Chicago Medical Center. The medical group on file is Southwest Infectious Disease & Internal Medicine. Dmand AI also links Dr. Wajahat to 1 more hospital, 1 breast imaging center, 1 group practice or clinic, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wajahat practices, 6 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Wajahat's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Wajahat is licensed in Ohio.

CMS data shows 1,167 Medicare services from Dr. Wajahat across 4 procedure codes in 2024, for 297 Medicare patients. Medicare paid $78,910 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 297 Medicare patients who saw Dr. Wajahat in 2024. The largest group is 75 to 84, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 55% are also on Medicaid. Their average risk score is 4.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wajahat's median patient age at 74, with 47% women.

In 2024, Dr. Wajahat wrote 169 Medicare Part D claims for 92 patients. 86% of them were for generic drugs. CMS names the drug for 87 of them, across 5 drugs with 11 or more claims each, at $5,596 in total drug cost. In 2023, CMS named 477 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Wajahat for performance year 2024, reported as part of a group. Dr. Wajahat accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 39 general payments to Dr. Wajahat from 11 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 87% of the total. Allergan Inc. paid the most, $162.